For pregnant women with sickle-cell disease (SCD) previously controlled with hydroxycarbamide (hydroxyurea), consider continuation or recommencement (after the first trimester) of the medication in the context of shared decision making involving the woman and a multidisciplinary team that includes experts in SCD and pregnancy. Base risk–benefit analyses on the woman’s symptom severity, stage of pregnancy and her views and preferences.